Safety and Pharmacokinetics of MCI-186 in Subjects With Acute Ischemic Stroke
| Condition | Acute Ischemic Stroke |
|---|---|
| Phase | Phase 2 |
| Sponsor | Shionogi |
| Status | Completed |
| Enrollment | 36 participants |
| Interventions | MCI-186 |
| Start date | Feb 28, 2009 |
| Completion date | Nov 30, 2010 |
| Results posted | May 12, 2014 |
Summary
The objectives of this study are to assess the safety, tolerability and local tolerance, and to investigate the plasma levels and terminal elimination half life of MCI-186, and to review the routine clinical and neurological assessments data of MCI-186 in subjects with acute ischemic stroke.
Number of Participants That Experienced Adverse Events
| MCI-186 Cohort1 | 0 participants |
|---|---|
| MCI-186 Cohort2 | 0 participants |
| Placebo Group | 0 participants |
| MCI-186 Cohort1 | 0 participants |
| MCI-186 Cohort2 | 2 participants |
| Placebo Group | 1 participants |
Open in BENITIONS View on ClinicalTrials.gov
Other trials for this condition
- Closed-loop Deep Brain Stimulation to Treat Refractory Neuropathic Pain — Prasad Shirvalkar, MD, PhD
- Women's Health Initiative Strong and Healthy Study — Fred Hutchinson Cancer Center
- Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke — Shionogi
- Zambia Stroke Unit Study — Johns Hopkins University
- Tracking Post-stroke Walking Improvements From the Clinic Into the Home — Western University of Health Sciences
- Improving How Older Adults at Risk for Cardiovascular Outcomes Are Selected for Care Coord — Weill Medical College of Cornell University